

Rossana Berardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6955013/publications.pdf>

Version: 2024-02-01

318
papers

9,816
citations

41258

49
h-index

60497

81
g-index

325
all docs

325
docs citations

325
times ranked

16432
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	5.1	503
2	Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases. <i>Journal of Clinical Oncology</i> , 2007, 25, 4431-4437.	0.8	360
3	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. <i>Annals of Oncology</i> , 2009, 20, 227-230.	0.6	294
4	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
5	Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). <i>Annals of Oncology</i> , 2007, 18, 510-517.	0.6	258
6	Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , 2004, 22, 4772-4778.	0.8	235
7	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 46-57.	3.4	201
8	PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. <i>Cancer Treatment Reviews</i> , 2015, 41, 114-121.	3.4	161
9	Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 6690-6696.	3.2	159
10	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. <i>Oncologist</i> , 2019, 24, e327-e337.	1.9	131
11	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology</i> , The, 2008, 9, 39-44.	5.1	130
12	Nuclear Factor- κ B Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3930-3935.	0.8	121
13	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. <i>Cancer Treatment Reviews</i> , 2016, 48, 20-24.	3.4	118
14	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. <i>Clinical Lung Cancer</i> , 2019, 20, 237-247.e1.	1.1	118
15	Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. <i>Annals of Oncology</i> , 2007, 18, 1660-1665.	0.6	116
16	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016, 7, 54564-54571.	0.8	116
17	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1757-1768.	2.0	110
18	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012, 23, 2072-2077.	0.6	108

#	ARTICLE	IF	CITATIONS
19	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 195.	1.1	101
20	Role of maspin in cancer. <i>Clinical and Translational Medicine</i> , 2013, 2, 8.	1.7	100
21	First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. <i>European Journal of Cancer</i> , 2020, 130, 155-167.	1.3	98
22	Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 447-455.	1.2	92
23	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. <i>European Journal of Cancer</i> , 2020, 128, 17-26.	1.3	85
24	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
25	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. <i>Journal of Cancer</i> , 2021, 9, e002421.		80
26	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 1755-1759.	2.9	79
27	Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers. <i>Breast</i> , 2019, 47, 85-92.	0.9	76
28	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
29	Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010, 127, 1941-1947.	2.3	67
30	Randomized phase III study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013, 111, 44-52.	1.3	67
31	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009, 9, 303.	1.1	66
32	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	1.1	66
33	Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. <i>Cancer Treatment Reviews</i> , 2004, 30, 451-459.	3.4	65
34	Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. <i>British Journal of Cancer</i> , 2013, 109, 1040-1050.	2.9	65
35	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	3.5	65
36	Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. <i>Surgery</i> , 2016, 159, 862-871.	1.0	65

#	ARTICLE	IF	CITATIONS
37	High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2021, 144, 41-48.	1.3	64
38	Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. <i>Annals of Oncology</i> , 2020, 31, 789-797.	0.6	62
39	State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 75-86.	2.0	61
40	Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations. <i>Cancers</i> , 2014, 6, 1351-1362.	1.7	61
41	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
42	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	5.1	59
43	High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 2004, 90, 1521-1525.	2.9	58
44	Mucinous Rectal Adenocarcinoma Can Be Associated to Tumor Downstaging after Preoperative Chemoradiotherapy. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1594-1603.	0.7	57
45	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. <i>International Journal of Cancer</i> , 2014, 134, 2772-2777.	2.3	57
46	Prognostic Role of Interleukin-1 β Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2339-2345.	0.8	56
47	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e74402.	1.1	56
48	The Role of HER3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. <i>Oncologist</i> , 2011, 16, 53-60.	1.9	55
49	5-fluorouracil pharmacogenomics: still rocking after all these years?. <i>Pharmacogenomics</i> , 2011, 12, 251-265.	0.6	54
50	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
51	Essential Role of Gli Proteins in Glioblastoma Multiforme. <i>Current Protein and Peptide Science</i> , 2013, 14, 133-140.	0.7	53
52	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. <i>Cell Adhesion and Migration</i> , 2015, 9, 14-21.	1.1	51
53	Hyponatremia in cancer patients: Time for a new approach. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 15-25.	2.0	50
54	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , 2020, 21, 498-508.e2.	1.1	50

#	ARTICLE	IF	CITATIONS
55	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
56	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
57	Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options. <i>Cancer Treatment Reviews</i> , 2011, 37, 169-177.	3.4	49
58	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 123-131.	3.4	49
59	A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. <i>Angiogenesis</i> , 2012, 15, 141-150.	3.7	48
60	Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival. <i>Frontiers in Oncology</i> , 2019, 9, 874.	1.3	48
61	Preoperative Maximum Oxygen Consumption Is Associated With Prognosis After Pulmonary Resection in Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2014, 98, 238-242.	0.7	47
62	Performance at Preoperative Stair-Climbing Test Is Associated With Prognosis After Pulmonary Resection in Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1796-1800.	0.7	46
63	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 221-231.	3.3	46
64	A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. <i>Translational Lung Cancer Research</i> , 2019, 8, 280-285.	1.3	46
65	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	1.3	45
66	Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. <i>Supportive Care in Cancer</i> , 2015, 23, 3095-3101.	1.0	44
67	Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. <i>Oncotarget</i> , 2016, 7, 26916-26924.	0.8	44
68	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014, 135, 763-773.	2.3	43
69	Chemotherapy for advanced gastric cancer: across the years for a standard of care. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 797-808.	0.9	41
70	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF- κ B activation. <i>British Journal of Cancer</i> , 2008, 98, 71-76.	2.9	41
71	Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 905-910.	0.6	41
72	Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9067-9067.	0.8	41

#	ARTICLE	IF	CITATIONS
73	Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 445-449.	2.9	40
74	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , 2014, 46, 182-186.	0.4	40
75	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. <i>Oncotarget</i> , 2015, 6, 35087-35094.	0.8	40
76	<p>Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9363-9374.	0.9	40
77	Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. <i>British Journal of Cancer</i> , 2007, 97, 92-97.	2.9	39
78	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 164.	3.5	39
79	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 630-637.	3.3	38
80	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0152079.	1.1	38
81	Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). <i>Cancer Treatment Reviews</i> , 2018, 71, 76-87.	3.4	38
82	Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. <i>Breast</i> , 2019, 48, 7-16.	0.9	37
83	Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. <i>Lung Cancer</i> , 2005, 49, 371-376.	0.9	36
84	Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. <i>Oncotarget</i> , 2017, 8, 23871-23879.	0.8	36
85	Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncology</i> , 2003, 65, 198-203.	0.9	35
86	Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	35
87	COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 526-530.	0.6	34
88	Hyponatraemia"SIADH in lung cancer diagnostic and treatment algorithms. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 1-8.	2.0	34
89	Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2006, 53, 103-109.	0.9	33
90	Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2015, 23, 621-626.	1.0	33

#	ARTICLE	IF	CITATIONS
91	Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. <i>European Journal of Cancer</i> , 2003, 39, 1144-1149.	1.3	32
92	Pancreatic cancer: Progress in cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 27-38.	2.0	32
93	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.	3.5	32
94	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017, 8, 100708-100716.	0.8	32
95	Tremellimumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	1.7	31
96	Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. <i>ESMO Open</i> , 2022, 7, 100406.	2.0	31
97	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 765-773.	2.7	30
98	Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	0.8	30
99	Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. <i>Oncotarget</i> , 2016, 7, 82648-82657.	0.8	30
100	Managing hyponatremia in lung cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 711-719.	1.4	29
101	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	0.5	29
102	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020, 15, 495-501.	1.7	28
103	Gender Differences and Outcomes in Melanoma Patients. <i>Oncology and Therapy</i> , 2020, 8, 103-114.	1.0	28
104	Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 572-572.	0.7	28
105	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy? A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 264-274.	2.0	26
106	Prostate cancer: from Gleason scoring to prognostic grade grouping. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 433-440.	1.1	26
107	Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. <i>Annals of Oncology</i> , 2006, 17, 1661-1664.	0.6	25
108	New target therapies in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2006, 17, v148-v152.	0.6	24

#	ARTICLE	IF	CITATIONS
109	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. <i>Cancer Treatment Reviews</i> , 2009, 35, 451-462.	3.4	24
110	Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting. <i>Current Cancer Drug Targets</i> , 2010, 10, 46-54.	0.8	24
111	High CTLA-4 expression correlates with poor prognosis in thymoma patients. <i>Oncotarget</i> , 2018, 9, 16665-16677.	0.8	24
112	Clinical impact of different exosomesâ€™ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0215990.	1.1	24
113	Correlation between apparent diffusion coefficient of magnetic resonance imaging and tumor-infiltrating lymphocytes in breast cancer. <i>Radiologia Medica</i> , 2019, 124, 581-587.	4.7	24
114	Predictive ability of a drug-based score in patients with advanced nonâ€™small-cell lung cancer receiving first-line immunotherapy. <i>European Journal of Cancer</i> , 2021, 150, 224-231.	1.3	24
115	Locally advanced rectal cancer: The importance of a multidisciplinary approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 17279.	1.4	24
116	Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. <i>Anticancer Research</i> , 2013, 33, 2737-42.	0.5	24
117	The Gustave Roussy Immune (GRIIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. <i>Journal of Clinical Medicine</i> , 2021, 10, 1005.	1.0	23
118	Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. <i>Clinical Sarcoma Research</i> , 2013, 3, 6.	2.3	22
119	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 563.	1.0	22
120	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. <i>Scientific Reports</i> , 2017, 7, 45703.	1.6	22
121	Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 251-251.	0.7	22
122	Development of a patient-centered aggregate score to predict survival after lung resection for nonâ€™small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 146, 385-390.e2.	0.4	21
123	Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. <i>Annals of Oncology</i> , 2015, 26, 838-847.	0.6	21
124	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019, 9, 12993.	1.6	21
125	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptorâ€™positive, advanced breast cancer: A realâ€™world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	2.0	21
126	Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2012, 7, 104-110.	0.5	20

#	ARTICLE	IF	CITATIONS
127	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. PLoS ONE, 2018, 13, e0197035.	1.1	20
128	Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice. Journal of Translational Medicine, 2019, 17, 376.	1.8	20
129	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World Journal of Gastrointestinal Oncology, 2016, 8, 389.	0.8	20
130	Gastric cancer treatment: a systematic review. Oncology Reports, 2004, 11, 911-6.	1.2	20
131	Phase II, randomized trial of preoperative epirubicin-paclitaxel+Â~Âgefinitib with biomarker evaluation in operable breast cancer. Breast Cancer Research and Treatment, 2008, 110, 127-134.	1.1	19
132	Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Supportive Care in Cancer, 2016, 24, 3139-45.	1.0	19
133	SIADH: differential diagnosis and clinical management. Endocrine, 2017, 55, 311-319.	1.1	19
134	Practical issues for the management of hyponatremia in oncology. Endocrine, 2018, 61, 158-164.	1.1	19
135	Modifications of taste sensitivity in cancer patients: a method for the evaluations of dysgeusia. Supportive Care in Cancer, 2020, 28, 1173-1181.	1.0	19
136	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. Journal of Cellular Physiology, 2020, 235, 7900-7910.	2.0	19
137	Post-progression outcomes of NSCLC patients with PD-L1 expression â%¥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. European Journal of Cancer, 2021, 148, 24-35.	1.3	19
138	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	1.3	19
139	A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2008, 62, 673-678.	1.1	18
140	The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer, 2017, 16, 38-43.	1.0	18
141	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
142	The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases. Supportive Care in Cancer, 2019, 27, 1255-1261.	1.0	18
143	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy. Npj Breast Cancer, 2021, 7, 47.	2.3	18
144	Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. Oncotarget, 2015, 6, 19305-19315.	0.8	18

#	ARTICLE	IF	CITATIONS
145	Desmoplastic Small Round Cell Tumour: A Description of Two Cases and Review of the Literature. <i>Oncology</i> , 2003, 64, 14-17.	0.9	17
146	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. <i>Tumori</i> , 2006, 92, 384-388.	0.6	17
147	Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?. <i>Lung Cancer</i> , 2010, 68, 433-437.	0.9	17
148	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 397-401.	1.4	17
149	Chromium Exposure and Germinal Embryonal Carcinoma: First Two Cases and Review of the Literature. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2015, 78, 1-6.	1.1	17
150	Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 5773-5782.	0.5	17
151	Scientia Potentia Est: How the Italian World of Oncology Changes in the COVID-19 Pandemic. <i>JCO Global Oncology</i> , 2020, 6, 1017-1023.	0.8	17
152	<p>Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): Optimal Management<p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 663-672.	0.9	17
153	Electrolyte disorders in advanced non-small cell lung cancer patients treated with immune check-point inhibitors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102974.	2.0	17
154	Optimal management of resected gastric cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1605-1618.	0.9	16
155	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987772.	1.4	16
156	Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 69.	1.3	16
157	Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy. <i>Tumor Biology</i> , 2004, 25, 106-110.	0.8	15
158	Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 1051-1054.	2.9	15
159	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 37-43.	1.1	15
160	Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. <i>Cancer Treatment Reviews</i> , 2014, 40, 495-506.	3.4	15
161	Healthcare cost of HER2-positive and negative breast tumors in the United States (2012&€“2035). <i>Cancer Treatment Reviews</i> , 2017, 60, 12-17.	3.4	15
162	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e811-e814.	1.1	15

#	ARTICLE	IF	CITATIONS
163	Systemic treatment for lung carcinoids: from bench to bedside. <i>Clinical and Translational Medicine</i> , 2019, 8, 22.	1.7	15
164	Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. <i>BMJ Open</i> , 2020, 10, e034393.	0.8	15
165	Elderly Patients with Advanced Colorectal Cancer: Tolerability and Activity of Chemotherapy. <i>Tumori</i> , 2005, 91, 463-466.	0.6	14
166	Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. <i>Supportive Care in Cancer</i> , 2015, 23, 1295-1302.	1.0	14
167	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
168	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. <i>Current Oncology Reports</i> , 2010, 12, 175-185.	1.8	13
169	Developments in the management of advanced soft-tissue sarcoma – olaratumab in context. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 833-842.	1.0	13
170	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , 2020, 150, 123-131.	0.9	13
171	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020, 38, 1774-1783.	1.2	13
172	Endometriosis-associated Clear Cell Carcinoma of the Abdominal Wall After Caesarean Section: A Case Report and Review of the Literature. <i>In Vivo</i> , 2020, 34, 2147-2152.	0.6	13
173	Regulation of Hippo, TGFÎ²/SMAD, Wnt/Î²-Catenin, JAK/STAT, and NOTCH by Long Non-Coding RNAs in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 657965.	1.3	13
174	Cancer patient perspective in the arena of COVIDâ€™19 pandemic. <i>Psycho-Oncology</i> , 2022, 31, 39-45.	1.0	13
175	Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study. <i>Oncologist</i> , 2022, 27, e723-e730.	1.9	13
176	Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. Expert Opinion on Pharmacotherapy, 2009, 10, 2245-2258.	0.9	12
177	The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. <i>ESMO Open</i> , 2016, 1, e000004.	2.0	12
178	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	1.1	12
179	Seroprevalence of SARS-CoV-2â€™Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1503.	1.0	12
180	Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 223-236.	2.0	11

#	ARTICLE	IF	CITATIONS
181	Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. <i>Core Evidence</i> , 2010, 5, 61.	4.7	11
182	MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, S257-S258.	0.5	11
183	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 501-502.	1.2	11
184	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
185	Lung cancer prognosis: can histological patterns and morphological features have a role in the management of lung cancer patients?. <i>Annals of Translational Medicine</i> , 2017, 5, 353-353.	0.7	11
186	Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study. <i>Clinical Breast Cancer</i> , 2021, 21, e489-e496.	1.1	11
187	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	0.8	11
188	Nuclear factor- κ B predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. <i>Digestive and Liver Disease</i> , 2012, 44, 617-622.	0.4	10
189	Resected biliary tract cancers: A novel clinical "pathological score correlates with global outcome. <i>Digestive and Liver Disease</i> , 2013, 45, 70-74.	0.4	10
190	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 541.e7-541.e13.	0.8	10
191	Role of DCE-MR in predicting breast cancer subtypes. <i>Radiologia Medica</i> , 2018, 123, 753-764.	4.7	10
192	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	1.3	10
193	Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 937-943.	1.5	10
194	Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	10
195	BRCA mutations and gastrointestinal cancers: When to expect the unexpected?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 565-580.	0.9	10
196	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , 2016, 17, 777-782.	1.0	10
197	Gastric cancer treatment: a systematic review. <i>Oncology Reports</i> , 0, , .	1.2	10
198	New Insights into Hormonal Therapies in Uterine Sarcomas. <i>Cancers</i> , 2022, 14, 921.	1.7	10

#	ARTICLE	IF	CITATIONS
199	Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. <i>Annals of Oncology</i> , 2011, 22, 897-902.	0.6	9
200	Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma. <i>Tumori</i> , 2016, 102, 190-195.	0.6	9
201	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 426-431.	0.9	9
202	Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis. <i>Lung Cancer</i> , 2020, 146, 318-326.	0.9	9
203	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolmunology</i> , 2020, 9, 1710389.	2.1	9
204	Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 55.	0.5	9
205	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. <i>Anti-Cancer Drugs</i> , 2010, 21, 459-464.	0.7	8
206	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. <i>Digestive and Liver Disease</i> , 2011, 43, 225-230.	0.4	8
207	Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib.. <i>Canadian Urological Association Journal</i> , 2014, 8, 121.	0.3	8
208	Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2020, 20, e89-e98.	1.1	8
209	Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. <i>Lung Cancer</i> , 2020, 140, 71-79.	0.9	8
210	High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases. <i>Frontiers in Oncology</i> , 2020, 10, 588862.	1.3	8
211	First prospective data on breast cancer patients from the multicentre italian bone metastasis database. <i>Scientific Reports</i> , 2021, 11, 4329.	1.6	8
212	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer â€” A GISCAD phase II randomized trial. <i>European Journal of Cancer</i> , 2021, 148, 422-429.	1.3	8
213	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	1.6	8
214	Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab. <i>Frontiers in Oncology</i> , 2021, 11, 736104.	1.3	8
215	Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?. <i>Current Cancer Drug Targets</i> , 2013, 13, 313-325.	0.8	8
216	Maspin expression is a favorable prognostic factor in non-small cell lung cancer. , 2012, 34, 72-8.		8

#	ARTICLE	IF	CITATIONS
217	The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. <i>Digestive and Liver Disease</i> , 2011, 43, 194-198.	0.4	7
218	Patient and Caregiver Needs in Oncology. An Italian Survey. <i>Tumori</i> , 2015, 101, 621-625.	0.6	7
219	Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 254-255.	0.8	7
220	Long-term responders to anti-HER2 therapies: A case report and review of the literature. <i>Molecular and Clinical Oncology</i> , 2017, 8, 147-152.	0.4	7
221	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	0.6	7
222	Potential benefit of β -glucans as adjuvant therapy in immuno-oncology: a review. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, .	0.5	7
223	The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience. <i>Cancers</i> , 2021, 13, 5539.	1.7	7
224	Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 \geq 50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 483-488.	0.8	7
225	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2467-2478.	0.9	6
226	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. <i>Eur Urol</i> 2015;68:912-4. <i>European Urology</i> , 2016, 70, e72-e74.	0.9	6
227	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	2.2	6
228	A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy. <i>Translational Lung Cancer Research</i> , 2021, 10, 2163-2171.	1.3	6
229	International consensus on severe lung cancer—the first edition. <i>Translational Lung Cancer Research</i> , 2021, 10, 2633-2666.	1.3	6
230	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
231	Effective prevention of 5-fluorouracil-induced superficial phlebitis by ketoprofen lysine salt gel. <i>American Journal of Medicine</i> , 2003, 115, 415-417.	0.6	5
232	Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype. <i>Clinical Breast Cancer</i> , 2018, 18, e231-e235.	1.1	5
233	Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing. <i>Cancers</i> , 2020, 12, 2724.	1.7	5
234	Expectations and psychological issues before genetic counseling: analysis of distress determinant factors. <i>Hereditary Cancer in Clinical Practice</i> , 2020, 18, 10.	0.6	5

#	ARTICLE	IF	CITATIONS
235	The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093660.	0.6	5
236	Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS471-TPS471.	0.8	5
237	Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients. <i>Oncotarget</i> , 2017, 8, 75914-75923.	0.8	5
238	Are liver nested stromal epithelial tumors always low aggressive?. <i>World Journal of Gastroenterology</i> , 2017, 23, 8248-8255.	1.4	5
239	New findings on thymic epithelial tumors: Something is changing. <i>World Journal of Clinical Oncology</i> , 2015, 6, 96.	0.9	5
240	BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2021, 13, 5741-5751.	0.6	5
241	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	1.4	5
242	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. <i>Journal of Hematology and Oncology</i> , 2022, 15, 9.	6.9	5
243	Compliance with breast and cervical cancer screening programs in women: results from a population-based study. <i>Tumori</i> , 2013, 99, 565-71.	0.6	5
244	The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients. <i>Oncology</i> , 2005, 68, 212-216.	0.9	4
245	Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 281-287.	1.5	4
246	Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinical Pathologic Score Correlates With Global Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1437-1443.	0.4	4
247	A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. <i>Annals of Oncology</i> , 2012, 23, 1081-1082.	0.6	4
248	Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors). <i>Current Drug Targets</i> , 2016, 17, 748-749.	1.0	4
249	Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. <i>Oncology Reports</i> , 2016, 36, 755-762.	1.2	4
250	Personality (at Intrapsychic and Interpersonal Level) Associated With Quality of Life in Patients With Cancer (Lung and Colon). <i>Cancer Control</i> , 2019, 26, 107327481988056.	0.7	4
251	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
252	Hyponatremia is a Predictor of Clinical Outcome for Resected Biliary Tract Cancers: A Retrospective Single-Center Study. <i>Oncology and Therapy</i> , 2020, 8, 115-124.	1.0	4

#	ARTICLE	IF	CITATIONS
253	Prognostic factors in advanced pancreatic cancer patients receiving second-line chemotherapy: a single institution experience. <i>Translational Cancer Research</i> , 2018, 7, 1190-1198.	0.4	4
254	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. <i>European Journal of Cancer</i> , 2022, 166, 202-207.	1.3	4
255	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. <i>Digestive and Liver Disease</i> , 2012, 44, 74-79.	0.4	3
256	Gender differences and outcome of melanoma patients. <i>Journal of Translational Medicine</i> , 2015, 13, P13.	1.8	3
257	Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1499-1505.	1.3	3
258	KEYNOTE-024: goodbye to chemotherapy?. <i>Journal of Thoracic Disease</i> , 2019, 11, S428-S432.	0.6	3
259	MALAT1 as a Versatile Regulator of Cancer: Overview of the Updates from Predatory Role as Competitive Endogenous RNA to Mechanistic Insights. <i>Current Cancer Drug Targets</i> , 2021, 21, 192-202.	0.8	3
260	Maspin Staining and Its Use as Biomarker in Lung Cancer. <i>Biomarkers in Disease</i> , 2015, , 345-358.	0.0	3
261	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016, 11, e0159146.	1.1	3
262	Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase. , 2019, 2, 787-802.		3
263	Correlation between everolimus discontinuation or dose reduction induced by stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 448-448.	0.8	3
264	A Mixed-approach program To help women with breast cancer stay active (MOTIVE program): A pilot-controlled study. <i>Heliyon</i> , 2021, 7, e08252.	1.4	3
265	Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature. <i>I Supplementi Di Tumori</i> , 2003, 2, S45-7.	0.1	3
266	A cost-benefit analysis of chemotherapy for gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2109-2114.	0.9	2
267	Somatostatin analogs: is one better than other?. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 817-819.	1.4	2
268	Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review. <i>Oncology and Therapy</i> , 2020, 8, 147-160.	1.0	2
269	Seminoma Retroperitoneal Relapse 23 Years After Surgery. <i>Oncology and Therapy</i> , 2021, 9, 239-245.	1.0	2
270	Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. <i>Current Oncology</i> , 2021, 28, 3525-3536.	0.9	2

#	ARTICLE	IF	CITATIONS
271	Different effects of sunitinib, sorafenib, and pazopanib on inducing cancer cell death: The role of autophagy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 270-270.	0.8	2
272	LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. <i>Journal of Clinical Oncology</i> , 2014, 32, 497-497.	0.8	2
273	Emergency diagnosis of lung cancer: An international problem.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6536-6536.	0.8	2
274	Epidermal growth factor receptor status in stages of resected non-small cell lung cancer: implications for treatment with epidermal growth factor receptor inhibitors. , 2011, 33, 196-204.		2
275	Adenocarcinoma arising from ileoanal J-pouch mucosa. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E57-E58.	0.9	1
276	Professional failure: how do oncologists feel it?. <i>Annals of Oncology</i> , 2011, 22, 2696-2697.	0.6	1
277	The role of an immune checkpoint score in resected non-small cell lung cancer patientsâ€™ prognosis. <i>Journal of Thoracic Disease</i> , 2017, 9, 3480-3482.	0.6	1
278	A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay. <i>Familial Cancer</i> , 2018, 17, 215-224.	0.9	1
279	Acute Peripheral Motor Neuropathy Induced by Oxaliplatin-Related Hypokalaemia. <i>Oncology and Therapy</i> , 2020, 8, 161-169.	1.0	1
280	An observational retrospective analysis of the main metastatic site and corresponding locoregional treatment as a prognostic factor in metastatic gastric cancer. <i>Oncology Letters</i> , 2021, 21, 267.	0.8	1
281	Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1
282	Lynch syndrome-associated lung cancer: pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.5	1
283	Re: Comments on â€“High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced nonâ€“small cell lung cancer patientsâ€™. <i>European Journal of Cancer</i> , 2021, 153, 267-269.	1.3	1
284	Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach?. <i>World Journal of Clinical Oncology</i> , 2016, 7, 131.	0.9	1
285	Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. <i>Tumori</i> , 2011, 97, 275-9.	0.6	1
286	Pre-operative treatment modalities in gastric cancer patients. <i>Annals of Oncology</i> , 2005, 16, iv106-iv109.	0.6	0
287	â€œBiliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature reviewâ€• [Cancer Treatment Reviews 32(5) (2006) 333â€“347]. <i>Cancer Treatment Reviews</i> , 2007, 33, 497.	3.4	0
288	Locally advanced rectal cancer: new findings in anticancer therapy. <i>Colorectal Cancer</i> , 2013, 2, 585-601.	0.8	0

#	ARTICLE	IF	CITATIONS
289	PD62-05 NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: DIFFERENCES IN CLINICAL AND PATHOLOGICAL RESPONSE. Journal of Urology, 2017, 197, .	0.2	0
290	Yes-associated protein and immunosuppressive microenvironment in pancreatic cancer development: a new strategy to improve immunotherapy efficacy?. Journal of Thoracic Disease, 2017, 9, 1798-1801.	0.6	0
291	Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO). Supportive Care in Cancer, 2021, 29, 851-858.	1.0	0
292	Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	0
293	Contrasting Fake News in Oncology: The First Declaration of Good Communication. JCO Global Oncology, 2021, 7, 740-746.	0.8	0
294	Role of docetaxel in the treatment of advanced gastric carcinoma. Clinical Management Issues, 2009, 3, 43-52.	0.3	0
295	Adjuvant Treatment After Surgical Resection. , 2012, , 187-194.		0
296	A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor.. Journal of Clinical Oncology, 2012, 30, 636-636.	0.8	0
297	Targeting Hedgehog in pancreatic cancer: An innovative approach but not for all tumors.. Journal of Clinical Oncology, 2013, 31, 205-205.	0.8	0
298	Locally advanced or metastatic pancreatic tumors: Molecular biology may help to know it and to select the optimal treatment.. Journal of Clinical Oncology, 2013, 31, 201-201.	0.8	0
299	Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience.. Journal of Clinical Oncology, 2013, 31, 415-415.	0.8	0
300	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 421-421.	0.8	0
301	Pretreatment neutrophil to lymphocyte ratio may be an useful tool in predicting survival in early triple-negative breast cancer patients.. Journal of Clinical Oncology, 2014, 32, 1111-1111.	0.8	0
302	Abstract 2220: Impact of single-nucleotide polymorphisms (SNPs) on thymic hyperplasia and tumors outcome. , 2014, , .		0
303	Anxiety, depression in lung cancer and the predictive role of unmet needs: Data from a national multicenter study (E-LUNG).. Journal of Clinical Oncology, 2016, 34, 10062-10062.	0.8	0
304	Abstract 3401: Impact of VEGF and VEGFR polymorphisms on neuroendocrine tumors of the gastro-entero-pancreatic system (GEPNETs) outcome. , 2016, , .		0
305	Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).. Journal of Clinical Oncology, 2017, 35, 1095-1095.	0.8	0
306	Abstract LB-256: Impact of metformin on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNETs) receiving everolimus and/or somatostatin analogues: A sensitivity analysis of the PRIME-NET (pancreatic multicentric, retrospective, italian metformin) study. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
307	Family history of cancer as surrogate predictor for immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: The FAMI-L1 study.. Journal of Clinical Oncology, 2019, 37, 2559-2559.	0.8	0
308	Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.. Journal of Clinical Oncology, 2019, 37, TPS4151-TPS4151.	0.8	0
309	TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. Journal of Clinical Oncology, 2020, 38, TPS783-TPS783.	0.8	0
310	Multicenter Italian bone metastasis database: First prospective data on breast cancer patients.. Journal of Clinical Oncology, 2020, 38, e13072-e13072.	0.8	0
311	TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. Journal of Clinical Oncology, 2020, 38, TPS4666-TPS4666.	0.8	0
312	Contrasting fake news in oncology: The first declaration of good communication.. Journal of Clinical Oncology, 2020, 38, e19231-e19231.	0.8	0
313	The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesions. Journal of Thoracic Disease, 2020, 12, 7245-7256.	0.6	0
314	Management of lung cancer patients during COVID-19 pandemic: dos, donâ€™ts and donâ€™t knows. Exploration of Targeted Anti-tumor Therapy, 2022, , 321-336.	0.5	0
315	Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.. Journal of Clinical Oncology, 2022, 40, 2595-2595.	0.8	0
316	FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9145-TPS9145.	0.8	0
317	Influence of type 2 diabetes mellitus and concomitant anti-diabetic medications in patients with metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e16301-e16301.	0.8	0
318	Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy.. Journal of Clinical Oncology, 2022, 40, 4153-4153.	0.8	0